The NCI Cancer Center Support Grant to the Abramson Cancer Center (ACC) has funded the Biostatistics Core continuously since its establishment in 1978. This Core was rated ?Exceptional? in the last renewal. The Core provides expert biostatistical guidance in the design, conduct, and analysis of research projects conducted by cancer center members, and offers training in the fundamentals of design and analysis to the Penn cancer research community. Core personnel are prepared not only to apply existing methods of design and analysis, but also to modify or develop new methods to address novel design and analysis issues arising in cancer research projects. A major responsibility is to support the design of clinical trials; as such, the Biostatistics Core plays a key role in the Protocol Review and Monitoring System, particularly through the Clinical Trials Scientific Review and Monitoring Committee. Access to the Core is limited to ACC members. Andrea Troxel, ScD, Professor of Biostatistics, has served as a Core member since 2004 and as Director of the Biostatistics Core since 2014; she leads an accomplished and highly collaborative team drawn from the faculty of the Penn Department of Biostatistics and Epidemiology. During the current project period, the Biostatistics Core has continued to be a dynamic presence in the ACC, providing collaborative biostatistical support services across the spectrum of cancer research. Participation of the Core has been essential to the funding of numerous currently funded grants, including three P01s, three P50s (including two SPOREs), one P60, one P42, two U01s, and one U54 in areas such as skin cancer, ovarian cancer, prostate and testicular cancer, thoracic cancers, esophageal cancer, smoking cessation research, and environmental carcinogenesis, as well as 25 R01s, six R21s, several K-series grants, and numerous foundation and state government grants. During the current project period, the Core has added strength in statistical methods for genetic data, clinical prediction, and pediatric oncology. Core members have co-authored roughly 400 publications in the current project period. In the upcoming grant cycle, the Core will assume responsibility for data management in the ACC, subsuming the role of the Biomedical Data Coordination Core. In summary, the Biostatistics Core is composed of a superbly qualified, productive, versatile and highly collaborative team of biostatistics and data management professionals who are deeply involved in supporting research throughout the ACC. 78 ACC members have used the Core in the reporting period of 10/01/13-09/31/14, and ACC member usage constitutes 100% of the total Core usage. CCSG support represents 21% of the proposed Core budget, with the remainder coming from other research grants and Institutional funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-44
Application #
9836818
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications